Data to Be Presented at 58th Annual Meeting of The American Society of Huma...( NOVATO Calif. Nov. 6 /- BioMarinP...)

NOVATO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that data from clinical studies of Kuvan(R) (sapropterin dihydrochloride), Naglazyme(R) (galsulfase) and enzyme replacement therapies for MPS IVA (Morquio Syndrome) and Pompe disease will be presented at the 58th Annual Meeting of the American Society of Human Genetics (ASHG) in Philadelphia, Pennsylvania, November 11-15, 2008.

"We look forward to a number of poster presentations that will address a variety of investigator-sponsored trials now in progress. Results from these studies will add to our growing data set for Kuvan and Naglazyme and increase our understanding about the long term safety and efficacy of the drugs across different patient populations," said Chief Medical Officer Emil Kakkis, M.D., Ph.D.

The following posters will be featured:

590/W - "Implications of absence of clinical phenotype on Morquio A mice: Why rodents do not require skeleton keratan sulfate?"

752/W - "Intrathecal (IT) enzyme replacement therapy (ERT) for symptomatic spinal cord compression (SCC) in a MPS VI child: safety, efficacy, and pitfalls"

763/W - "Therapeutic response after two years of Galsulfase ERT in five adult patients with MPS VI"

2353/W - "MPS Brazil-Network: 4 years improving diagnosis and management of mucopolysaccharidoses in Brazil"

772/T - "PKU treatment with tetrahydrobiopterin (sapropterin) during pregnancy"

773/T - "A new strategy using sapropterin and placebo to determine the predictive value of mutation analysis towards identifying BH4 responsive hyperphenylalanemia"

774/T - "Interim results of a Phase II, multicenter, open-label study of sapropterin dihydrochlori
'/>"/>